• Alessandro Dal Maso, Martina Lorenzi, Alessandra Ferro, Sara Pilotto, Fabiana Cecere, Alessandro Follador, Valentina Polo, Alessandro Del Conte, Giulia Sartori, Marco Giavarra, Daniela Scattolin, Stefano Indraccolo, Stefano Frega, Giovanna De Maglio, Jessica Menis, Laura Bonanno, Fiorella Calabrese, Valentina Guarneri, PierFranco Conte, and Giulia Pasello.
• Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, 35128, Italy.
• Future Oncol. 2021 Jul 1; 17 (19): 2513-2527.

AbstractAims: This study describes real-world outcomes of pretreated EGFR T790M-positive (T790M+) advanced non-small-cell lung cancer patients progressing after first- or second-generation tyrosine kinase inhibitors and receiving osimertinib, compared with T790M-negative (T790M-) patients. We have also described progression patterns and treatment sequences. Patients & methods: This is a retrospective multicenter Italian observational study including consecutive Caucasian patients referred between 2014 and 2018. Results: 167 patients were included. Median progression-free survival was 9.8 months (95% CI: 8.3-13.3) for T790M+ and 6.0 months (95% CI: 4.9-7.2) for T790M- patients, respectively. Median overall survival was 20.7 months (95% CI: 18.9-28.4) for T790M+ and 10.6 months (95% CI: 8.6-23.6) for T790M- patients, respectively. The T790M mutation correlated with absence of new sites of disease. After progression, most T790M+ patients continued osimertinib, whereas most T790M- patients received a different treatment line. Conclusion: Better outcomes were shown in patients receiving osimertinib. A more limited progression pattern for T790M+ was suggested.

41 keywords...

hide…